NCT00445705 - Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome | Biotech Hunter

Enrollment

211

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Fibromyalgia

Interventions

DRUG

placebo

Part A: Placebo every 12 hours for 4 weeks

DRUG

AGN 203818

Part A: AGN 203818 3 mg every 12 hours for 4 weeks

DRUG

AGN 203818

Part A: AGN 203818 20 mg every 12 hours for 4 weeks

DRUG

AGN 203818

Part A: AGN 203818 60 mg every 12 hours for 4 weeks

Trial Locations (3)

Canton

Geneva

Stanmore